A5009879217- Immune cells in cancer
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
- Cancer Cells and Metastasis
- Cancer Research and Treatments
- Sarcoma Diagnosis and Treatment
- Neonatal Respiratory Health Research
- CAR-T cell therapy research
- Airway Management and Intubation Techniques
- Nanoplatforms for cancer theranostics
- Nanoparticle-Based Drug Delivery
- MXene and MAX Phase Materials
- Graphene and Nanomaterials Applications
- Chemical Reactions and Isotopes
- Pulmonary Hypertension Research and Treatments
- Inhalation and Respiratory Drug Delivery
- Beetle Biology and Toxicology Studies
- Radiopharmaceutical Chemistry and Applications
Virginia Commonwealth University
2020-2025
Georgia State University
2014
Aerosol drug delivery via high flow nasal cannula (HFNC), bubble continuous positive airway pressure (CPAP), and synchronized inspiratory (SiPAP) has not been quantified in spontaneously breathing premature infants.The purpose of this study was to compare aerosol HFNC, CPAP, SiPAP a model simulated preterm infant.The types CPAP systems nebulizer positions used during therapy will impact deposition infants.Quantitative, comparative, in-vitro study.A breath simulator set infant settings (VT :...
Osteosarcoma (OS), the most common primary bone cancer across all ages, predominantly metastasizing to lungs. At diagnosis, 20% of OS patients present gross lung metastases (OSLM), while others harbor undetectable micrometastases. Despite current treatments, including systemic chemotherapy and experimental therapeutics like immune checkpoint inhibitors, 5-year survival rate for OSLM continues be low (ca. 20-30%), making it leading cause death in patients. Thus, there is an urgent need...
Abstract Osteosarcoma (OS) predominantly metastasizes to the lungs, with approximately 20% of patients presenting detectable osteosarcoma lung metastases (OSLM) at first diagnosis, while most other are expected have undetectable micrometastases. OSLM is associated a 5-year survival rate only 20%, which not improved over past four decades. Current pharmacotherapies curative, and experimental immune checkpoint inhibitor therapies shown minimal efficacy. PLX-3397 (PLX), an FDA-approved...
The lungs are major sites of metastases for several cancer types, including breast (BC). Prognosis and quality life BC patients that develop pulmonary negatively impacted. development strategies to slow the growth relieve symptoms lung (BCLM) is thus an important goal in management BC. However, systemically administered first line small molecule chemotherapeutics have poor pharmacokinetic profiles biodistribution significant off-target toxicity, severely compromising their effectiveness. In...
Abstract Osteosarcoma (OS) metastasizes primarily and almost exclusively to the lungs. The survival rate decreases significantly for patients who develop OS lung metastasis (OSLM). Purpose: To assess safety efficacy of colony-stimulating factor-1 receptor inhibitor (CSF-1Ri) (Pexidartinib; PLX) in shifting OSLM tumor microenvironment (TME) an anti-tumorigenic state upon local delivery lungs a syngeneic mouse model OSLM. Methods: PLX repeated pulmonary administration (9 doses, every other day...